All IndicationsOncology
🎗️
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
1
Companies
1
Drug Programs
0
Phase 3
0
Upcoming PDUFAs
Competitors
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| 4503.T Astellas Pharma Inc. | epirubicin | Phase 2 | — | — | — |
Development Stage Distribution
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.